GITR Antibodies in Cancer: Not Ready for Prime Time

Clin Cancer Res. 2022 Sep 15;28(18):3905-3907. doi: 10.1158/1078-0432.CCR-22-1489.

Abstract

Glucocorticoid-induced TNF receptor (TNFR)-related protein (GITR) agonistic antibodies are expected to increase the antitumor response mainly by reducing the effect of Foxp3+ T-regulatory cells. TRX-518 is a novel GITR agonist that has shown good pharmacodynamic activity by depleting regulatory T cells (Tregs) in preclinical models, with limited clinical activity demonstrated in patients with advanced solid tumors. See related article by Davar et al., p. 3990.

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Cell Line, Tumor
  • Deoxycytidine / analogs & derivatives
  • Gemcitabine
  • Glucocorticoid-Induced TNFR-Related Protein / immunology
  • Humans
  • Neoplasms* / metabolism
  • Nivolumab*
  • T-Lymphocytes, Regulatory / immunology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Glucocorticoid-Induced TNFR-Related Protein
  • Deoxycytidine
  • Nivolumab
  • pembrolizumab
  • Gemcitabine